The Messenger: Moderna, the Vaccine, and the Business Gamble That Changed the World
Author: Peter Loftus
Publisher: Harvard Business Review Press
Pages: 269
Price: Rs 1,250
For anyone who has followed, even casually, the trajectory of the Coronavirus pandemic, Moderna is a household name today because of its mRNA vaccine. Yet at the end of 2019, it was a languishing biotech start-up with no real products and dismal financials. mRNA was an exciting area from the science point of view. But Moderna had been in existence for a decade and investors were getting more than slightly disillusioned by it. It had raised funding
For anyone who has followed, even casually, the trajectory of the Coronavirus pandemic, Moderna is a household name today because of its mRNA vaccine. Yet at the end of 2019, it was a languishing biotech start-up with no real products and dismal financials. mRNA was an exciting area from the science point of view. But Moderna had been in existence for a decade and investors were getting more than slightly disillusioned by it. It had raised funding